Adipose-Derived Mesenchymal Stromal Cells for Chronic Myocardial Ischemia (MyStromalCell Trial): Study Design

Abstract

Adipose tissue represents an abundant, accessible source of multipotent adipose-derived stromal cells (ADSCs). Animal studies have suggested that ADSCs have the potential to differentiate in vivo into endothelial cells and cardiomyocytes. This makes ADSCs a promising new cell source for regenerative therapy to replace injured tissue by creating new blood vessels and cardiomyocytes in patients with chronic ischemic heart disease. The aim of this special report is to review the present preclinical data leading to clinical stem cell therapy using ADSCs in patients with ischemic heart disease. In addition, we give an introduction to the first-in-man clinical trial, MyStromalCell Trial, which is a prospective, randomized, double-blind, placebo-controlled study using culture-expanded ADSCs obtained from adipose-derived cells from abdominal adipose tissue and stimulated with VEGF-A(165) the week before treatment.

Mesenchymal Stromal Cells Mediate Aspergillus Hyphal Extract-Induced Allergic Airway Inflammation by Inhibition of the Th17 Signaling Pathway

“…In addition, MSCs possess significant immunomodulatory functions, and adoptive transfer of non-human leukocyte antigenmatched allogeneic MSCs is feasible and appears to be safe. These properties have been demonstrated in a spectrum of animal models of inflammatory and immune-based diseases and have led to clinical trials in a wide variety of immune and inflammatory diseases [19][20][21][22] as well as recent clinical approval for therapeutic use in severe refractory pediatric graft-versus-host disease in Canada [23]. MSCs have also been demonstrated to have efficacy in mouse models of pulmonary diseases including acute lung injury, bronchopulmonary dysplasia, and chronic obstructive pulmonary diseases including asthma and emphysema [24,25].…”

Good manufacturing practice-compliant isolation and culture of human adipose derived stem cells

“…These cells also successfully differentiate into adipocytes, osteoblasts, and chondrocytes, and could be trans-differentiated into other mesoderm cell types such as insulin producing cells (Karaoz et al, 2013;Moshtagh et al, 2013), hepatocytes (Aurich et al, 2009;Lee et al, 2012;Okura et al, 2010), and neuronal-like cells (Cardozo et al, 2010;Rezanejad et al, 2014). (Sandor et al, 2014), non-revascularizable critical limb ischemia (Bura et al, 2014), acute myocardial infarction and heart failure (Panfilov et al, 2013), complex perianal fistula in Crohn's disease (de la Portilla et al, 2013;Garcia-Olmo et al, 2009), and chronic myocardial ischemia (Qayyum et al, 2012). Some in vitro culture procedures of ADSCs were suggested.…”

Angiogenic properties of adipose tissue-derived multipotent mesenchymal stromal cells in patients with coronary heart disease

“…Терапевтическая эффективность этих клеток изучена во многих экспериментах на клинически релевант-ных моделях патологий у животных [2]. Сегодня известны результаты нескольких клинических испы-таний (APOLLO, PRECISE, MyStromalCell Trial), где была показана возможность лечения острой и хро-нической ИБС с помощью внутрикоронарного вве-дения ММСК ЖТ [4][5][6]. Однако эффективность лечения ишемии тканей после трансплантации ауто-логичных ММСК ЖТ, как и других аутологичных ММСК, недостаточно высокая.…”